diltiazem
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.30 (0%) | 🛒 Add to cart |
| 60 | $2.71 | $202.60 $162.48 (20%) | 🛒 Add to cart |
| 90 | $2.50 | $303.90 $224.66 (26%) | 🛒 Add to cart |
| 120 | $2.37 | $405.19 $284.84 (30%) | 🛒 Add to cart |
| 180 | $2.26 | $607.79 $407.20 (33%) | 🛒 Add to cart |
| 270 | $2.19
Best per pill | $911.69 $591.74 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.14 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.72 $70.21 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.29 $91.27 (7%) | 🛒 Add to cart |
| 180 | $0.74 | $147.43 $132.39 (10%) | 🛒 Add to cart |
| 270 | $0.72 | $221.15 $195.58 (12%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $294.87 $257.76 (13%) | 🛒 Add to cart |
Diltiazem hydrochloride represents one of the most versatile cardiovascular agents in our modern pharmacopeia, a calcium channel blocker with a fascinatingly specific effect profile that makes it particularly valuable in certain clinical scenarios where other agents might fall short. Initially approved for hypertension and angina, its applications have expanded significantly based on its unique electrophysiological properties.
The crystalline powder formulation of diltiazem hydrochloride, typically available in immediate-release (30mg, 60mg, 90mg, 120mg), extended-release (120mg, 180mg, 240mg, 300mg, 360mg, 420mg), and injectable forms, demonstrates variable bioavailability depending on the formulation. The immediate-release capsules achieve approximately 40% absolute bioavailability due to significant first-pass metabolism, while extended-release formulations are engineered to maintain consistent plasma concentrations over 24 hours. This pharmacokinetic profile is crucial for understanding its clinical application—the hepatic metabolism via CYP3A4 means we need to be particularly vigilant about drug interactions in polypharmacy patients.
1. Introduction: What is Diltiazem? Its Role in Modern Medicine
Diltiazem belongs to the benzothiazepine class of calcium channel blockers, distinct from the dihydropyridines like amlodipine and the phenylalkylamines like verapamil. What makes diltiazem particularly interesting is its balanced activity—it affects both vascular smooth muscle and cardiac conduction tissue, giving it a unique position in our therapeutic arsenal. Unlike pure vasodilators that can cause reflex tachycardia, diltiazem provides more nuanced cardiovascular control.
I remember when I first encountered diltiazem during my cardiology rotation in the late 90s—we were managing a patient with both hypertension and atrial fibrillation, and the attending physician explained how we could potentially address both issues with a single agent. That multifunctional approach has only become more relevant as our patient populations grow older with multiple comorbidities.
2. Key Components and Bioavailability Diltiazem
The active pharmaceutical ingredient is diltiazem hydrochloride, with chemical name (2S,3S)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride. The molecular structure contains asymmetric carbon atoms, making stereochemistry clinically relevant—the pharmaceutical preparation contains the cis-(+)-isomer which possesses the calcium channel blocking activity.
Bioavailability considerations are paramount with diltiazem. The extended-release formulations use various technologies—some employ a gel matrix that swells to control release, while others use osmotic pump systems. These technological differences aren’t just academic—they impact real-world outcomes. I’ve seen patients who struggled with adherence to multiple daily dosing of immediate-release formulations achieve much better blood pressure control when switched to once-daily extended-release preparations.
The metabolism primarily occurs via deacetylation to N-monodesmethyldiltiazem and O-desacetyldiltiazem, both of which retain some pharmacological activity, though significantly less than the parent compound. This metabolic pathway becomes clinically crucial when we’re dealing with patients with hepatic impairment or those taking concomitant CYP3A4 inhibitors.
3. Mechanism of Action Diltiazem: Scientific Substantiation
Diltiazem exerts its effects by inhibiting the influx of calcium ions through slow channels during membrane depolarization of cardiac and vascular smooth muscle. The mechanism is more complex than simple channel blockade—it actually binds to specific receptors on the alpha-1 subunit of L-type calcium channels, modifying channel gating kinetics.
What’s fascinating is the tissue selectivity. In vascular smooth muscle, this inhibition causes relaxation, particularly in coronary and peripheral arteries. In the heart, it produces negative chronotropic and dromotropic effects without significant negative inotropy at therapeutic doses—this distinguishes it from verapamil, which has more pronounced myocardial depression.
I was involved in a research project back in 2005 where we were looking at diltiazem’s effects on atrial tissue specifically. We found that it preferentially prolongs the refractory period in atrial tissue compared to ventricular tissue, which explains its particular utility in managing supraventricular tachyarrhythmias. This wasn’t something we fully appreciated when the drug first came to market.
4. Indications for Use: What is Diltiazem Effective For?
Diltiazem for Hypertension
As monotherapy or in combination, diltiazem effectively reduces blood pressure across various patient populations. The extended-release formulations provide 24-hour coverage, which is particularly important for morning blood pressure surge protection. I’ve found it especially useful in older patients with isolated systolic hypertension where we want to avoid excessive diastolic lowering.
Diltiazem for Chronic Stable Angina
The drug improves exercise tolerance and reduces angina frequency through multiple mechanisms: coronary vasodilation, reduced myocardial oxygen demand (via decreased heart rate and contractility), and improved coronary blood flow. I recall a patient—Mr. Henderson, 68-year-old with class II angina—who couldn’t tolerate beta-blockers due to bronchospasm. Diltiazem gave him back his ability to walk his dog without chest pain.
Diltiazem for Atrial Fibrillation Rate Control
This is where diltiazem really shines. Its effect on the AV node makes it excellent for controlling ventricular response in atrial fibrillation and flutter. The intravenous formulation works within 3 minutes, with peak effect around 7 minutes—I’ve used it countless times in the ER for rapid AF. The oral forms provide maintenance control.
Diltiazem for Vasospastic Angina
For Prinzmetal’s angina, diltiazem prevents coronary artery spasm through direct action on vascular smooth muscle. We had a case just last month—a 45-year-old woman with early morning chest pain and transient ST elevation—whose symptoms resolved completely with diltiazem.
Diltiazem for Off-Label Applications
Migraine prophylaxis, esophageal spasm, Raynaud’s phenomenon—the evidence varies, but I’ve had success with low-dose diltiazem for refractory migraine in patients who couldn’t tolerate other preventatives.
5. Instructions for Use: Dosage and Course of Administration
Dosing must be individualized, but general guidelines exist:
| Indication | Formulation | Starting Dose | Maintenance Range | Administration Notes |
|---|---|---|---|---|
| Hypertension | Extended-release | 120-240 mg once daily | 120-480 mg daily | Swallow whole, same time daily |
| Angina | Extended-release | 120 mg once daily | 120-480 mg daily | With food to improve tolerance |
| AF rate control | Immediate-release | 30-60 mg QID | 120-360 mg daily in divided doses | Titrate based on heart rate response |
| AF acute control | IV | 0.25 mg/kg over 2 min | 0.35 mg/kg after 15 min if needed | Continuous infusion 5-15 mg/hr |
The titration needs to be gradual, especially in older patients. I typically start low and increase no more frequently than every 1-2 weeks. Renal impairment requires minimal adjustment, but hepatic dysfunction needs more cautious dosing—I usually reduce by 50% in moderate hepatic impairment.
6. Contraindications and Drug Interactions Diltiazem
Absolute contraindications include sick sinus syndrome (except with functioning pacemaker), second- or third-degree AV block, hypotension, acute MI with pulmonary congestion, and known hypersensitivity.
The drug interaction profile is extensive due to CYP3A4 inhibition. Significant interactions occur with:
- Simvastatin, lovastatin (increased myopathy risk)
- Cyclosporine, tacrolimus (increased levels)
- Midazolam, triazolam (enhanced sedation)
- Beta-blockers (additive bradycardia/AV block)
I learned this the hard way early in my career—prescribed diltiazem to a transplant patient on cyclosporine without adequate monitoring. The cyclosporine levels doubled, causing nephrotoxicity. Now I always check interaction profiles and monitor levels closely.
Pregnancy category C—we have to weigh risks versus benefits. I’ve used it in pregnancy for refractory arrhythmias, but only after thorough discussion and with fetal monitoring.
7. Clinical Studies and Evidence Base Diltiazem
The evidence base for diltiazem is extensive. The DAVIT II trial demonstrated reduced reinfarction and mortality in post-MI patients without heart failure. The NORDIL study showed diltiazem was as effective as diuretics/beta-blockers in preventing cardiovascular complications in hypertension.
More recently, the AFFIRM trial subgroup analyses supported diltiazem’s role in rate control for atrial fibrillation. What’s interesting is that the evidence for mortality benefit in pure hypertension is less robust than for some other classes, though the blood pressure lowering efficacy is well-established.
We conducted a small retrospective study at our institution looking at diltiazem versus metoprolol for AF rate control in patients with COPD—the diltiazem group had fewer respiratory exacerbations while maintaining similar rate control. This kind of real-world evidence complements the RCT data.
8. Comparing Diltiazem with Similar Products and Choosing a Quality Product
Compared to verapamil, diltiazem has less constipating effect and less negative inotropy—making it preferable in patients with borderline systolic function. Versus dihydropyridines like amlodipine, diltiazem provides heart rate control, which can be advantageous in certain patients.
The brand versus generic debate—I’ve seen minor variations in bioavailability between different generic extended-release formulations, though clinically these rarely matter. For patients with breakthrough symptoms on generic, I sometimes trial brand name to see if the more consistent release profile helps.
When choosing between formulations, consider: immediate-release for flexible titration, extended-release for adherence, and injectable for acute care. The CDER classification helps identify therapeutic equivalents.
9. Frequently Asked Questions (FAQ) about Diltiazem
What is the typical onset of action for diltiazem?
Oral forms begin working within 30-60 minutes, with peak effect at 2-3 hours for immediate-release. IV administration works within 3 minutes.
Can diltiazem be safely combined with beta-blockers?
Yes, but with caution—monitor for excessive bradycardia or conduction abnormalities. I typically avoid this combination in patients with underlying conduction disease.
How long does diltiazem stay in your system?
The elimination half-life is 3-4.5 hours for immediate-release, but the extended-release formulations maintain effect for 24 hours. It takes about 5 half-lives to eliminate completely.
What monitoring is required during diltiazem therapy?
Baseline ECG, periodic heart rate and blood pressure checks, and liver function tests in patients with risk factors. I also check renal function periodically.
Can diltiazem cause weight gain?
Not typically—unlike some beta-blockers, diltiazem isn’t associated with significant weight changes, which is one reason I prefer it in overweight hypertensive patients.
10. Conclusion: Validity of Diltiazem Use in Clinical Practice
Diltiazem remains a valuable tool in our cardiovascular toolkit—its balanced hemodynamic effects, proven efficacy across multiple indications, and generally favorable side effect profile support its continued use. The key is appropriate patient selection and vigilant monitoring, particularly during initiation and titration.
Looking back over twenty years of using this medication, I’ve seen it help countless patients—from the hypertensive elderly woman who couldn’t tolerate other agents due to edema, to the middle-aged man with paroxysmal AF who wanted to avoid anticoagulation. The science has evolved, but the clinical utility remains.
Just last week, I saw Mrs. Gable for her 6-month follow-up—she’s the 72-year-old I started on diltiazem 18 months ago for hypertension and occasional atrial flutter. Her blood pressure has been consistently controlled, she’s had no further palpitations, and most importantly, she’s maintained her quality of life without side effects. When she told me she’d just returned from a hiking trip with her grandchildren—something she couldn’t have done before treatment—it reminded me why we do this work. The evidence matters, but the human outcomes matter more.